title: Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
abstract: Azithromycin and clarithromycin were paired with other antibiotics to test synergistic activity against 300 multidrug-resistant pathogens isolated from cystic fibrosis (CF) patients. Clarithromycin-tobramycin was most active against Pseudomonas aeruginosa and inhibited 58% of strains. Azithromycin-trimethoprim-sulfamethoxazole, azithromycin-ceftazidime, and azithromycin-doxycycline or azithromycin-trimethoprim-sulfamethoxazole inhibited 40, 20, and 22% of Stenotrophomonas maltophilia, Burkholderia cepacia complex, and Achromobacter (Alcaligenes) xylosoxidans strains, respectively.
authors.affiliation: Department of Pediatrics, Columbia University, New York, New York 10032, USA. LS5@columbia.edu
authors.forename: Lisa
authors.initials: L
authors.lastname: Saiman
authors.forename: Yunhua
authors.initials: Y
authors.lastname: Chen
authors.forename: Pablo San
authors.initials: PS
authors.lastname: Gabriel
authors.forename: Charles
authors.initials: C
authors.lastname: Knirsch
mesh_terms: D000421:Alcaligenes / Q000187:drug effects*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016956:Burkholderia cepacia / Q000187:drug effects*; D003550:Cystic Fibrosis / Q000382:microbiology*; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004357:Drug Synergism; D006801:Humans; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D020615:Stenotrophomonas maltophilia / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents; D018942:Macrolides